Clinical Trial Update: Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating fecal microbiota transplantation in patients with unresectable hepatocellular carcinoma who progress on first-line therapy with at…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna | Conditions: Hepato Cellular Carcinoma (HCC) | Phase 2 | Status: RECRUITING